The Fox Chase Chemical Diversity Center, Inc. (FCCDC)


The Fox Chase Chemical Diversity Center Announces Troriluzole is in Clinical Trials for the Treatment of Alzheimer's


Doylestown, PA. August 21, 2019 - Troriluzole was designed and prepared at FCCDC funded originally by two SBIR grants from the National Institutes of Health, and it is currently in clinical trials for the treatment of Alzheimer's disease being development by Biohaven Pharmaceutical as described here: